The qCXL platform employs a customised treatment planning engine and real-time ultrasound monitoring for precision.

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

Scientists have reached a major milestone in animal-to-human transplant research as the U.S. Food and Drug Administration has approved the first human clinical trials for kidney transplants from ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

The MarketWatch News Department was not involved in the creation of this content. SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine ...

In reinstating human ADME to its portfolio, SGS strengths its ability to support drug development programmes with critical early clinical data. FANC approval enables SGS to reintroduce ¹⁴C human ADME ...

Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...

A burdensome regulatory environment is pushing clinical trials overseas. Jacob Becraft is the co-founder and CEO of Strand Therapeutics.

TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...